Literature DB >> 18294743

A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses.

Young Mo Sohn1, J B Tandan, Sutee Yoksan, Min Ji, Heechoul Ohrr.   

Abstract

Out of 98 subjects who had participated in the 2000 JE vaccination campaign, 69 people were enrolled in the tests of 2004 and 2005 for the evaluation of long term immune response of a single dose of live attenuated SA14-14-2 JE vaccine. 89.9% of study subjects (62/69) had maintained a high level of neutralizing antibody until 2004 as their GMT was measured as 133 (Min 11, Max 2991). Forty-four subjects were still positive in 2005, 5 years after JE vaccination, and their neutralizing antibody positive rate was significantly higher than that of 69 age-sex matched unvaccinated control subjects: 63.8% (44/69) vs. 14.5% (10/69) (P<0.05). Twenty-four subjects (Group 1) who were seronegative for neutralizing antibody at the 2005 test were given a second dose for revaccination in 2006. Also 49 seronegative (Group 2) subjects who were enrolled as a control group in 2005 were given one dose of primary JE vaccine in 2006. Seven days after vaccination, seropositive rate was discovered to be 76.5% (13/17) and 168.52 (Min 38, Max 2173) in Group 1, while no seroconversion in Group 2. On the 30th day, seropositive rate and GMT were 82.4% (14/17) and 392.01 (Min 22, Max 2197) in Group 1, while 75.7% (28/37) and 45.72 (Min 12, Max 505) in Group 2, respectively. We observed the persistence of neutralizing antibody of single dose of live attenuated SA14-14-2 JE vaccine, 89.9% after 4 years and 63.8% after 5 years, and a rapid secondary immune response on the seventh day after booster dose among those who had been seronegative in spite of the first dose of vaccine. Single dose of live JE vaccine could be effective to provide a long-term protection in JE endemic area, where natural boosting is quite probable in the vaccinees. However, further studies should be carried out to support whether one dose of live JE vaccine is sufficient for people in JE non-endemic area.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18294743     DOI: 10.1016/j.vaccine.2008.01.021

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

Review 1.  Immunogenicity and safety of currently available Japanese encephalitis vaccines: a systematic review.

Authors:  Xing Li; Shu-Juan Ma; Xie Liu; Li-Na Jiang; Jun-Hua Zhou; Yi-Quan Xiong; Hong Ding; Qing Chen
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children.

Authors:  Emmanuel Feroldi; Maria Rosario Capeding; Mark Boaz; Sophia Gailhardou; Claude Meric; Alain Bouckenooghe
Journal:  Hum Vaccin Immunother       Date:  2013-02-26       Impact factor: 3.452

3.  Genetic and phenotypic properties of vero cell-adapted Japanese encephalitis virus SA14-14-2 vaccine strain variants and a recombinant clone, which demonstrates attenuation and immunogenicity in mice.

Authors:  Gregory D Gromowski; Cai-Yen Firestone; José Bustos-Arriaga; Stephen S Whitehead
Journal:  Am J Trop Med Hyg       Date:  2014-10-13       Impact factor: 2.345

4.  Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults.

Authors:  Peter E Nasveld; Andrew Ebringer; Nathan Elmes; Sonya Bennett; Sutee Yoksan; John Aaskov; Karen McCarthy; Niranjan Kanesa-thasan; Claude Meric; Mark Reid
Journal:  Hum Vaccin       Date:  2010-12-01

5.  Decreases in Both the Seroprevalence of Serum Antibodies and Seroprotection against Japanese Encephalitis Virus among Vaccinated Children.

Authors:  Ran Wang; Lyu Xie; Na Gao; Dongying Fan; Hui Chen; Peigang Wang; Hongning Zhou; Jing An
Journal:  Virol Sin       Date:  2019-03-25       Impact factor: 4.327

Review 6.  Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.

Authors:  Nagendra R Hegde; Milind M Gore
Journal:  Hum Vaccin Immunother       Date:  2017-02-22       Impact factor: 3.452

7.  Biological and genetic properties of SA₁₄-14-2, a live-attenuated Japanese encephalitis vaccine that is currently available for humans.

Authors:  Byung-Hak Song; Gil-Nam Yun; Jin-Kyoung Kim; Sang-Im Yun; Young-Min Lee
Journal:  J Microbiol       Date:  2012-08-25       Impact factor: 3.422

8.  Cellular inflammatory response to flaviviruses in the central nervous system of a primate host.

Authors:  Olga A Maximova; Lawrence J Faucette; Jerrold M Ward; Brian R Murphy; Alexander G Pletnev
Journal:  J Histochem Cytochem       Date:  2009-07-06       Impact factor: 2.479

9.  Recurrence of Japanese encephalitis epidemic in Wuhan, China, 2009-2010.

Authors:  Quan Hu; Banghua Chen; Zerong Zhu; Junhua Tian; Yu Zhou; Xiaoyong Zhang; Xin Zheng
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

10.  Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III.

Authors:  Yi-Chin Fan; Hsien-Chung Chiu; Li-Kuang Chen; Gwong-Jen J Chang; Shyan-Song Chiou
Journal:  PLoS Negl Trop Dis       Date:  2015-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.